Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 5,500 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on December 10, 2024 (the “Grant Date”), in connection with the commencement of employment.
- 12/13/2024
|
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
- SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA.
- 11/19/2024
|
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates
- Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to loss of $10.25 per share a year ago.
- 11/06/2024
|
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
- SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2024.
- 11/06/2024
|
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
- FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting .
- 10/31/2024
|
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 95,000 shares of the Company's stock (the “Inducement Grants”) to newly hired employees on October 8, 2024 (the “Grant Date”), in connection with the commencement of employment. Included in the aggregate number is the grant of an option to purchase 75,000 shares to Dr. Hardean Achneck, in connection with the commencement of his role as Chief Medical Officer.
- 10/11/2024
|
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
- SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately.
- 10/01/2024
|
Aligos Therapeutics to Present at Investor Conferences in October
- SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will participate at two investor conferences being webcast in October:
- 09/30/2024
|
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects.
- 09/19/2024
|
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
- SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT.
- 09/18/2024
|
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 3,500 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on September 10, 2024 (the “Grant Date”), in connection with the commencement of employment.
- 09/13/2024
|
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?
- Here is how Aligos Therapeutics, Inc. (ALGS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
- 09/10/2024
|
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%
- The average of price targets set by Wall Street analysts indicates a potential upside of 648.1% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 08/21/2024
|
Aligos Therapeutics Announces Reverse Stock Split
- SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. The reverse stock split will become effective at 12:01 am ET on Monday, August 19, 2024. The Company's common stock is expected begin trading on the Nasdaq Capital Market under the same symbol (ALGS) on a split-adjusted basis at the market open on August 19, 2024 with the new CUSIP number 01626L 204.
- 08/15/2024
|
What Makes Aligos Therapeutics (ALGS) a New Buy Stock
- Aligos Therapeutics (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 08/09/2024
|
Aligos Therapeutics Strengthens Board with Two New Independent Directors
- SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Governance Committee as Chair and Ms. Chavez will join the Audit Committee.
- 08/08/2024
|
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
- Amoytop to sponsor a Phase 1b exploratory clinical study evaluating the efficacy and safety of ALG-000184 in combination with PEGBING® (Mipeginterferon alfa-2b) in CHB patients
- 07/22/2024
|
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
- SOUTH SAN FRANCISCO, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Johns Hopkins University School of Medicine, to discuss the unmet need and current treatment landscape for patients with chronic hepatitis B (CHB), positive data from the Phase 1b study of ALG-000184, development plans, and the chronic suppression regulatory pathway on Thursday, July 18, 2024 at 3:00pm ET/12:00pm PT.
- 07/10/2024
|
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
- SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.
- 06/05/2024
|
Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now
- Aligos Therapeutics (ALGS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 06/04/2024
|
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
- FOSTER CITY, Calif.--(BUSINESS WIRE)-- #PFIC--Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress.
- 05/29/2024
|
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
- SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy. The abstracts released today can be found on the EASL website at www.easlcongress.eu.
- 05/22/2024
|
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
- Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) with topline safety and efficacy data anticipated in early Q4 2024.
- 05/21/2024
|
After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)
- Aligos Therapeutics (ALGS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 05/16/2024
|
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
- SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company's first quarter 2024 financial results on Tuesday, May 7, 2024, after the close of the U.S. financial markets.
- 04/30/2024
|
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
- Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting
- 04/25/2024
|
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
- After reaching an important support level, Aligos Therapeutics, Inc. (ALGS) could be a good stock pick from a technical perspective. ALGS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
- 03/27/2024
|
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
- SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced three oral presentations and one poster presentation at the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2024, being held March 27-31, 2024 in Kyoto, Japan.
- 03/27/2024
|
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
- SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2023.
- 03/12/2024
|
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
- SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company's fourth quarter 2023 financial results on Tuesday, March 12, 2024, after the close of the U.S. financial markets.
- 03/05/2024
|
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
- SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Leerink Partners Global Biopharma Conference 2024 being held in Miami, Florida on March 11-13, 2024.
- 02/26/2024
|
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
- SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos' Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET.
- 02/20/2024
|
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
- Here is how Aligos Therapeutics, Inc. (ALGS) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.
- 01/05/2024
|
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
- SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from December 3 – 7, 2023. The presentations can be found on the “Scientific Presentations & Conferences” section of the Aligos website (www.aligos.com).
- 12/07/2023
|
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, and the Aligos management team, will present at the 2023 Piper Sandler Healthcare Conference being held in New York on Thursday, November 30, 2023 at 12:30 p.m. ET.
- 11/20/2023
|
Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today?
- Aligos Therapeutics (NASDAQ:ALGS) stock is falling on Monday after the clinical-stage biopharmaceutical company announced plans for a porposed public share offering. According to a filing with the Securities and Exchange Commission (SEC), the selling stockholders are preparing to offer as many as 168,725,925 shares of ALGS stock.
- 11/20/2023
|
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
- The thyroid hormone receptor-beta ( THR- b) drug ALG-055009: Was well tolerated when oral daily doses up to 1.0 mg were given for 2 weeks in a Phase 1 study in hypercholesterolemic subjects Demonstrated favorable PK with low variability Dose responsively lowered lipid levels in study subjects Was well tolerated in animals following repeated daily dosing in 13 week toxicology studies Is more b selective and 5-47x more potent than resmetirom and VK-2809 parent Has a favorable overall risk-benefit profile which supports conducting a 12-week Phase 2a study in NASH subjects SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that clinical and nonclinical data for its thyroid hormone receptor-beta (THR-b) drug, ALG-055009, were presented Saturday, November 11th at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023.
- 11/13/2023
|
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
- Hepatitis B virus e antigen positive (HBeAg+) subjects dosed with once-daily 300mg ALG-000184 + entecavir for up to 48 weeks demonstrated:
- 11/10/2023
|
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
- November 16 Event to feature KOL perspective on Emerging HBV Therapies November 16 Event to feature KOL perspective on Emerging HBV Therapies
- 11/03/2023
|
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
- SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the third quarter 2023.
- 11/02/2023
|
Aligos Therapeutics Announces $92 Million Private Placement Financing
- Proceeds expected to fund the following: - NASH (ALG-055009): top line data from Phase 2a study (Q4 2024) - Hepatitis B/CAM-E (ALG-000184): Phase 2 enabling activities (H2 2024) - Funding expected to extend cash runway through end of 2025
- 10/23/2023
|
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
- - NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies
- 10/03/2023
|
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
- - Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024 - Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024
- 09/21/2023
|
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
- - Phase 1 study conduct complete with preliminary data indicating THR-beta agonist ALG-055009 was well-tolerated with a favorable PK profile and dose responsive changes in relevant biomarkers
- 07/19/2023
|
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
- SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data on its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.
- 06/07/2023
|
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. ET.
- 05/24/2023
|
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
- Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.84 per share a year ago.
- 05/04/2023
|
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
- SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company's first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets.
- 04/27/2023
|
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
- SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data out of five of its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023. The presentations will be available on the Scientific Presentations and Conferences page on Aligos' corporate website following the meeting.
- 04/11/2023
|
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
- Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/09/2023
|
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
- SOUTH SAN FRANCISCO, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 5:00 p.m. ET.
- 02/10/2023
|
4 Penny Stocks To Buy According To Analysts & Targets Over 600%
- Analysts have put these on their list of penny stocks to buy. Do you agree?
- 01/25/2023
|
4 Penny Stocks To Buy According To Insiders & Targets Up To 347%
- Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Insiders & Targets Up To 347% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/19/2023
|
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD's The Liver Meeting® 2022
- SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster presentations at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD).
- 10/21/2022
|
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
- SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company's third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.
- 10/19/2022
|
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute's 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
- Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023 Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023
- 10/18/2022
|
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present in at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 3:30 pm ET at the Marriot Marquis in New York City.
- 05/23/2022
|
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
- SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company's first quarter 2022 financial results on Wednesday, May 4, 2022 after the close of U.S. financial markets.
- 04/27/2022
|
Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022
- SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company's fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 after the close of U.S. financial markets.
- 03/02/2022
|
Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
- Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.
- 01/07/2022
|
Aligos Therapeutics Stock (ALGS): Why The Price Substantially Fell
- The stock price of Aligos Therapeutics Inc (NASDAQ: ALGS) fell by 56.74% in the most recent trading session. This is why it happened.
- 01/07/2022
|
Why Aligos Therapeutics Stock Crumbled Today
- The company is pulling the plug on a once-promising treatment targeting hepatitis B.
- 01/06/2022
|
Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 5:15 pm ET. Both the presentation and the Q&A session will be held virtually.
- 12/21/2021
|
Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Piper Sandler 33r d Annual Virtual Healthcare Conference being held from November 30 - December 2, 2021. The Aligos management team will also participate in virtual investor 1x1 meetings during the conference.
- 11/22/2021
|
All You Need to Know About Aligos Therapeutics, Inc. (ALGS) Rating Upgrade to Buy
- Aligos Therapeutics, Inc. (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 11/09/2021
|
Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD'S The Liver Meeting® 2021
- SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced upcoming poster presentations highlighting data relating to its chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) clinical programs at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held virtually November 12 - 15, 2021.
- 10/14/2021
|
Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study
- Aligos now evaluating three of its four chronic hepatitis B (CHB) portfolio drug candidates in clinical trials Aligos now evaluating three of its four chronic hepatitis B (CHB) portfolio drug candidates in clinical trials
- 10/11/2021
|
Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Cantor Virtual Global Healthcare Conference being held September 27-30, 2021.
- 09/20/2021
|
Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
- SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company's second quarter 2021 financial results on Thursday, August 5, 2021 after the close of U.S. financial markets.
- 07/29/2021
|
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
- SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share. In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock at the same terms and conditions. All of the shares of common stock are being offered by Aligos. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aligos, are expected to be approximately $83.6 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on July 6, 2021, subject to customary closing conditions.
- 06/30/2021
|
Aligos Therapeutics Announces Proposed Public Offering of Common Stock
- SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. In addition, Aligos intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock. All of the shares of common stock are being offered by Aligos. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 06/28/2021
|
Aligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence Blatt, Ph.D., MBA, CEO of Aligos, will present at the Jefferies Virtual Healthcare Conference being held June 1- 4, 2021. The presentation will be followed by a virtual Q&A session.
- 05/20/2021
|
ALGS Stock: 4.76% Increase Explanation
- The stock price of Aligos Therapeutics, Inc. (Nasdaq: ALGS) increased by 4.76% yesterday. This is why it happened.
- 04/15/2021
|
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
- Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients
- 04/14/2021
|
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
- The first drug candidate in Aligos's chronic hepatitis B portfolio to be administered to CHB patients The first drug candidate in Aligos's chronic hepatitis B portfolio to be administered to CHB patients
- 03/10/2021
|
Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections
- SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company delivered a presentation on its SARS-CoV-2 3CLpro inhibitor candidate, ALG-097111, at the 28th Conference on Retroviruses and Opportunistic Infections, being held virtually March 6 to March 10, 2021, during the meeting's Science Spotlight sessions on Saturday, March 6. Aligos performed all research in collaboration with Belgian University KU Leuven, in particular its Centre for Drug Design and Discovery (CD3), and the Rega Institute for Medical Research.
- 03/08/2021
|
Aligos (ALGS) in Focus: Stock Moves 5.6% Higher
- Aligos (ALGS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- 12/17/2020
|
Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH
- SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into an Exclusive License and Research Collaboration Agreement with Merck, known as MSD outside the United States and Canada, under which Merck and Aligos will apply Aligos' oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a non-alcoholic steatohepatitis (NASH) target and up to one additional target of interest in the cardiometabolic/fibrosis space.
- 12/07/2020
|
Aligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast. Please see additional details below:
- 11/13/2020
|
